Clopimozide

Clopimozide
Systematic (IUPAC) name
3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-6-chloro-1H-benzimidazol-2-one
Identifiers
CAS Number 53179-12-7
ATC code none
PubChem CID 65449
ChemSpider 58909
UNII 7C6TA32SD2 YesY
KEGG D02649
ChEMBL CHEMBL2104161
Chemical data
Formula C28H28ClF2N3O
Molar mass 495.99 g/mol

Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class.[1][2] It is very potent and has an extremely long duration of action, lasting at least one week with a single dose.[3][4][5] It was developed by Janssen Pharmaceutica but was never marketed.

See also

References

  1. De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica 59 (5): 561–74. doi:10.1111/j.1600-0447.1979.tb00256.x. PMID 37697.
  2. Knapen J, Bollen J, Brugmanns J, Rombaut N (1976). "[Treatment of chronic psychoses with oral clopimozide]". Acta Psychiatrica Belgica (in French) 76 (4): 644–57. PMID 798469.
  3. Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A (August 1975). "Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series". Arzneimittel-Forschung 25 (8): 1287–94. PMID 1242360.
  4. Floru L, Tegeler J (1978). "Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764)". Arzneimittel-Forschung 28 (2): 341–4. PMID 25071.
  5. Bobon J, Parent M, Toussaint C, Pinchard A (1976). "[Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)]". Acta Psychiatrica Belgica (in French) 76 (1): 138–43. PMID 970182.
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.